PDS Biotechnology Corp (NASDAQ:PDSB) — Stock Price
PDS Biotechnology Corp (NASDAQ:PDSB) is currently trading at $0.73 USD, down 5.66% today. Over the past 52 weeks, shares have ranged between $0.54 and $1.43. This page tracks PDS Biotechnology Corp's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of PDS Biotechnology Corp.
PDS Biotechnology Corp (PDSB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks PDS Biotechnology Corp's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
PDS Biotechnology Corp Income Statement — Revenue, Profit & Earnings by Year
PDS Biotechnology Corp's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $60.52K | $59.79K | $57.33K | $49.08K | $246.39K |
| Gross Profit | $-60.52K | $-59.79K | $-57.33K | $-49.08K | $-246.39K |
| Research & Development | $19.03 Million | $22.57 Million | $27.76 Million | $29.43 Million | $11.25 Million |
| SG&A | $12.52 Million | $13.49 Million | $15.02 Million | $12.24 Million | $10.18 Million |
| Total Operating Expenses | $31.54 Million | $36.26 Million | $43.05 Million | $41.67 Million | $21.44 Million |
| Operating Income | $-31.54 Million | $-36.32 Million | $-43.05 Million | $-41.67 Million | $-21.44 Million |
| EBITDA | $-30.30 Million | $-33.75 Million | $-40.09 Million | $-40.74 Million | $-21.43 Million |
| EBIT | $-30.33 Million | $-33.81 Million | $-40.14 Million | $-40.74 Million | $-21.43 Million |
| Interest Expense | $5.34 Million | $4.67 Million | $4.21 Million | $1.32 Million | $4.35K |
| Income Before Tax | $-35.67 Million | $-38.48 Million | $-44.35 Million | $-42.05 Million | $-21.43 Million |
| Income Tax Expense | $-1.17 Million | $-869.17K | $-1.41 Million | $-1.20 Million | $-4.52 Million |
| Net Income | $-34.50 Million | $-37.61 Million | $-42.94 Million | $-40.85 Million | $-16.92 Million |
PDS Biotechnology Corp Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes PDS Biotechnology Corp's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $30.49 Million | $45.36 Million | $59.39 Million | $77.01 Million | $67.20 Million |
| Total Current Assets | $28.25 Million | $45.05 Million | $59.06 Million | $76.48 Million | $66.84 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | $527.53K | $357.70K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $21.24 Million | $26.35 Million | $33.26 Million | $33.01 Million | $3.99 Million |
| Total Current Liabilities | $9.48 Million | $17.09 Million | $13.63 Million | $9.82 Million | $3.76 Million |
| Long-term Debt | $11.73 Million | $9.20 Million | $19.51 Million | $23.02 Million | — |
| Net Debt | $-9.79 Million | $-19.86 Million | $-32.71 Million | $-50.35 Million | $-64.75 Million |
| Total Stockholder Equity | $9.25 Million | $19.00 Million | $26.13 Million | $44.00 Million | $63.21 Million |
| Retained Earnings | $-216.61 Million | $-182.11 Million | $-144.50 Million | $-101.56 Million | $-60.70 Million |
PDS Biotechnology Corp Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how PDS Biotechnology Corp generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-27.75 Billion | $-35.03 Million | $-33.64 Million | $-25.71 Million | $-12.49 Million |
| Capital Expenditures | $0.00 | $29.00K | $4.00 | $4.00 | $4.00 |
| Free Cash Flow | $-27.75 Billion | $-35.06 Million | $-33.64 Million | $-25.71 Million | $-12.49 Million |
| Investing Cash Flow | — | $-29.00K | — | — | — |
| Financing Cash Flow | $12.77 Billion | $20.19 Million | $16.38 Million | $34.29 Million | $48.89 Million |
| Dividends Paid | — | — | — | $270.96 | — |
| Stock-Based Compensation | $4.11 Billion | $6.85 Million | $7.61 Million | $5.20 Million | $4.11 Million |
| Depreciation | $1.55 Billion | $21.11K | $17.36K | $86.00 | $5.36K |
| Change in Cash | $-14.98 Billion | $-14.87 Million | $-17.26 Million | $8.58 Million | $36.40 Million |
PDS Biotechnology Corp Earnings History — EPS Actual vs. Analyst Estimates
Track PDS Biotechnology Corp's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 20, 2026 | -0.13 | -0.18 | +27.78% |
| Mar 26, 2026 | -0.14 | -0.18 | +20.77% |
| Nov 13, 2025 | -0.19 | -0.21 | +9.52% |
| Aug 13, 2025 | -0.21 | -0.22 | +4.55% |
| May 13, 2025 | -0.21 | -0.25 | +14.88% |
| Mar 25, 2025 | -0.21 | -0.28 | +23.64% |
| Nov 12, 2024 | -0.29 | -0.28 | -3.57% |
| Aug 13, 2024 | -0.23 | -0.34 | +32.35% |